Outcome | Baseline | 6-months | 12-months | Eefect of intervention | p-value |
---|---|---|---|---|---|
Mean ± SD | Mean differences (95 % CI) |  | |||
Susceptibility to BC | |||||
 Intervention Group | 9.98 (3.92) | 10.58 (3.62) | 11.20 (3.62) | 0.42 (-0.26–1.10) | 0.22 |
 Control Group | 10.10 (3.84) | 10.19 (3.24) | 10.21 (3.76) | 0.0 |  |
Seriousness of BC | |||||
 Intervention Group | 19.60 (4.93) | 19.94 (4.50) | 20.04 (4.73) | 0.34 (-0.54–1.23) | 0.44 |
 Control Group | 19.50 (4.33) | 19.54 (4.31) | 19.51 (4.14) | 0.0 |  |
Benefits of BSE | |||||
 Intervention Group | 21.89 (4.19) | 23.56 (3.41) | 24.68 (3.74) | 1.09 (0.32–1.89) | 0.00* |
 Control Group | 22.22 (4.58) | 22.34 (4.34) | 22.30 (4.23) | 0.0 |  |
Barriers of BSE | |||||
 Intervention Group | 15.16 (4.69) | 12.89 (3.85) | 12.81 (3.95) | 0.95 (-1.74–-0.15) | 0.01* |
 Control Group | 14.56 (4.13) | 14.55 (4.28) | 14.60 (4.20) | 0.0 |  |
Confidence | |||||
 Intervention Group | 28.78 (7.27) | 32.41 (5.48) | 32.80 (7.55) | 1.66 (-0.55–2.77) | 0.00* |
 Control Group | 29.65 (6.10) | 29.71 (5.87) | 29.64 (5.62) | 0.0 |  |
Health Motivation | |||||
 Intervention Group | 26.52 (4.36) | 26.98 (3.67) | 27.67 (3.98) | 0.40 (-0.41–1.21) | 0.33 |
 Control Group | 26.62 (4.69) | 26.70 (4.18) | 26.65 (4.10) | 0.0 |  |
Total HBM score | |||||
 Intervention Group | 121.64 (14.34) | 126.15 (11.49) | 128.88 (12.74) | 2.62 (0.03–5.21) | 0.04* |
 Control Group | 122.72 (14.07) | 123.07 (12.79) | 123.01 (12.92) | 0.0 |  |